Critical Analysis: Gamida Cell (GMDA) vs. Its Peers

Gamida Cell (NASDAQ: GMDA) is one of 114 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Gamida Cell to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.


This table compares Gamida Cell and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gamida Cell N/A N/A N/A
Gamida Cell Competitors -5,041.11% -62.49% -26.17%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Gamida Cell and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gamida Cell 0 0 5 0 3.00
Gamida Cell Competitors 809 2698 5966 251 2.58

Gamida Cell currently has a consensus target price of $19.40, indicating a potential upside of 69.14%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.53%. Given Gamida Cell’s stronger consensus rating and higher possible upside, equities analysts clearly believe Gamida Cell is more favorable than its rivals.

Insider & Institutional Ownership

1.7% of Gamida Cell shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Gamida Cell and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Gamida Cell N/A -$52.93 million -1.09
Gamida Cell Competitors $934.72 million $204.36 million -1.34

Gamida Cell’s rivals have higher revenue and earnings than Gamida Cell. Gamida Cell is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


Gamida Cell beats its rivals on 6 of the 11 factors compared.

About Gamida Cell

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with's FREE daily email newsletter.